Hard charging Neurocrine hit with a sudden setback as Tourette study flops
Kevin Gorman, CEO of Neurocrine Biosciences, presents at a Jefferies investor conference in 2013. bloomberg/via getty images
Neurocrine has been on a roll for the past five weeks — right up to Tuesday evening.
First the FDA approved Ingrezza (valbenazine) for tardive dyskinesia in April, their first ever regulatory OK. Then just a few days ago its partner AbbVie came through with promising late-stage data for their endometriosis drug elagolix, outlicensed to them in 2010.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.